Details of the Drug Combination

General Information of Drug Combination (ID: DCAKJ2B)

Drug Combination Name

Taxol SNX-2112

Indication

Disease Entry	Status	REF
Amelanotic melanoma	Investigative	[1]

Component Drugs

Taxol DMUOT9V

SNX-2112 DMB5A80

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

High-throughput Screening Result

Testing Cell Line: A2058

Zero Interaction Potency (ZIP) Score: 12.36

Bliss Independence Score: 6.15

Loewe Additivity Score: 4.41

LHighest Single Agent (HSA) Score: 9.01

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Pancreatic cancer	2C10	Phase 3	[4]
Gastric adenocarcinoma	2B72	Phase 2	[5]
Ovarian cancer	2C73	Phase 2	[5]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[2]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of SNX-2112

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[6]

SNX-2112 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[6]
------------------------------------------------------------------------------------

SNX-2112 Interacts with 14 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)	OTLF4ZB1	IKKA_HUMAN	Decreases Expression	[7]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[7]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[7]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Decreases Expression	[7]
Endoplasmin (HSP90B1)	OT02XLBR	ENPL_HUMAN	Decreases Expression	[7]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Expression	[7]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[7]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Expression	[7]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Affects Localization	[7]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[7]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[7]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[7]
Heat shock protein 75 kDa, mitochondrial (TRAP1)	OTNG0L8J	TRAP1_HUMAN	Decreases Expression	[7]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 14 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCR57AE	ES2	Investigative	[8]
Breast and ovarian cancer syndrome	DCNZ06C	UWB1289+BRCA1	Investigative	[9]
Breast carcinoma	DCG6GFK	OCUBM	Investigative	[9]
Carcinoma	DCF49E1	OV90	Investigative	[9]
Carcinoma	DCS4BSH	MDAMB436	Investigative	[9]
Colon adenocarcinoma	DC9L7NX	LOVO	Investigative	[9]
Colon carcinoma	DCRIXV0	RKO	Investigative	[9]
Rectal adenocarcinoma	DCQZ3RL	SW837	Investigative	[9]
Adenocarcinoma	DCO160B	COLO320DM	Investigative	[1]
Adenocarcinoma	DCBAQG3	SW-620	Investigative	[1]
Germ cell tumour	DCXRNYU	PA1	Investigative	[1]
Large cell lung carcinoma	DCWVYYX	NCI-H460	Investigative	[1]
Malignant melanoma	DC7F7VA	A375	Investigative	[1]
Malignant melanoma	DC0QXK4	HT144	Investigative	[1]
Malignant melanoma	DCDRR2F	RPMI7951	Investigative	[1]
Malignant melanoma	DCJX4O1	SKMEL30	Investigative	[1]
Malignant melanoma	DC80HQW	UACC62	Investigative	[1]
Mesothelioma	DCPXR49	MSTO	Investigative	[1]
Non small cell carcinoma	DCM1MOO	SKMES1	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DCN603S	A2780	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCKN6S7	SK-OV-3	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 21 DrugCom(s)

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
7	The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-B and disruption of mitochondria-dependent pathways. Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.
8	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
9	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.